Tom McCarthy is Co-Founder & CEO of Molecule 2 Medicine Limited, a UK based consulting firm assisting clients with the discovery, development and commercialisation of new human therapeutics.
From 2006-2015 he was CEO of Spinifex Pharmaceuticals, an Australian and US biotech company developing first in class treatments for chronic pain without central nervous system side-effects. Spinifex Pharmaceuticals was purchased by Novartis in July 2015 for approximately US$700 million.
Previous positions include Vice President, Drug development at Starpharma Holdings Limited. He holds B.Sc. (Hons) and Ph.D. degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.